Eric Lefkofsky, The Man Behind Groupon is Focusing on Big Data to Propel His New Venture to Success

Through the exploitation of big data, a Chicago-based startup is keen on championing personalized cancer therapies. Currently, personalized health care in the fight against cancer is a preserve for the wealthy individuals because it involves sequencing of a person’s genome. The startup aims at leveraging the power of technology, specifically machine learning and data collected from patients who’ve battled cancer to create the new age treatments.

The startup is called Tempus. It was created by two entrepreneurs, Mr Eric Lefkofsky and Brad Keywell.

The company is a first in the collection of big data for cancer patients. It was built on the premise of availing big data for decision making in the fight against cancer. Tempus has based its main offices in Chicago.

Recently, the firm made a major pronouncement. It has entered into a partnership with the University of Chicago to provide genome sequencing and analysis of close to 1,000 breast cancer patients to the University. The breast cancer experts at the institution’s Department of Oncology will then use the data to come up with tailored treatment plans for patients. This approach to cancer treatment is hinged on the fact that different factors such as genetic makeup affect the response of a patient to treatment.

Big data is the basis upon which modern day professionals make decisions. In the long term, the data collected by Tempus will help guide doctors on how they can achieve effective treatment and better patient outcomes. Click here to know more.

Currently, oncologists make treatment decisions based on the limited knowledge they have learned. With big data, doctors will have more detailed and genetic-specific information that could help them make better decisions when administering therapies.

The irony of cancer treatment is that in as much as there are over 1.7 million new cases of cancer that are reported in the US yearly, the public healthcare has data for only 20,000 patients. To achieve the concept of personalized healthcare in the fight against cancer succeeds more resources have to be devoted towards collection and analysis of this data.

The founder of Tempus, Eric Lefkofsky is also the brainchild of acclaimed brands such Groupon, Lightbank, Drivin and Mediabank.

Facebook: https://www.facebook.com/eplefkofsky/

Omar Boraie Supports Important Research

A recent NewsWise article  highlights the crucial work being done at Rutgers University in precision medicine and mentions that an endowed chair was created in the name of supporter Omar Boraie at the Rutgers Cancer Institute to continue doing important research into cancers and their causes. Mr. Boraie, a developer in New Brunswick, recently made a generous donation of 1.5 million dollars to help fund the work being done at the Cancer Institute, and according to Patch.com, the Omar Boraie Chair in Genomic Science will ensure that groundbreaking research currently being done at Rutgers will continue.

Omar Boraie has studied chemistry himself and has long been interested in developments in cancer treatments. The director of the cancer institute at Rutgers has praised his generosity.

Specifically, the endowed chair will help fund research in genomics. Researchers at Rutgers are developing ways to create treatments for cancer at the genetic level, allowing them to customize approaches for individual patients. Rutgers is at the very cutting edge of using precision medicine and genomics to treat cancer, and researchers at the university are pioneering ways of attacking extremely rare forms of cancer that do not respond to conventional therapies.

The endowed chair has been named to Shridar Ganesan, MD, PhD, one of the leading scientists at the Cancer Institute. The research of Dr. Ganesan extends from the idea that cancer is not a single disease but rather a collection of diseases that require individualized treatments. He has made substantial progress at isolating and defining individual strains of the disease, and this has given hope to both scientists searching for cures and patients suffering from rare cancers.

The Rutgers Cancer Institute works closely with hospitals all over New Jersey to gather data, do research, conduct clinical tests and develop treatments. In short, Omar Boraie’s assistance to its mission has the potential to do a tremendous amount of good.

Reference: https://www.bloomberg.com/profiles/companies/0601263D:US-boraie-development-llc